¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"immunologic deficiency syndromes"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • folate deficiency anemia
    ¿±»ê°áÇ̺óÇ÷
  • iron deficiency anemia
    ö°áÇ̺óÇ÷
  • immune deficiency
    ¸é¿ª°áÇÌ
  • leukocyte adhesion deficiency
    ¹éÇ÷±¸ºÎÂø°áÇÌ
  • nutritional deficiency disease
    ¿µ¾ç°áÇ̺´
  • nutritional deficiency state
    ¿µ¾ç°áÇÌ»óÅÂ
  • nutritional deficiency syndrome
    ¿µ¾ç°áÇÌÁõÈıº
  • vitamin deficiency
    ºñŸ¹Î°áÇÌ(Áõ)
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antibody deficiency syndrome
    Ç×ü°áÇÌÁõÈıº
  • erythropoietin deficiency anemia
    ¿¡¸®Æ®·ÎÆ÷¿¡Æ¾°áÇ̺óÇ÷
  • folate deficiency anemia
    ¿±»ê°áÇÌ
  • iron deficiency anemia
    ö°áÇ̺óÇ÷
  • ceruloplasmin deficiency
    ¼¼·ê·ÎÇö󽺹ΰáÇÌ
  • complement deficiency
    µµ¿òü°áÇÌ
  • deficiency
    °áÇÌ(Áõ)
  • deficiency disease
    ¿µ¾ç°áÇ̺´
  • fat deficiency disease
    Áö¹æ°áÇÌÁõ
  • functional deficiency
    ±â´É°áÇÌ
  • histogenetic deficiency
    Á¶Á÷¹ß»ý°áÇÌ
  • immune deficiency
    (¢¡immunodeficiency) ¸é¿ª°áÇÌ
  • latent deficiency
    ÀáÀç°áÇÌÁõ
  • leukocyte adhesion deficiency
    ¹éÇ÷±¸ºÎÂø°áÇÌÁõ
  • mental deficiency
    Á¤½Å¹Ú¾à
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • immunologic system
    ¸é¿ª°è.
  • immunologic technique
    ¸é¿ªÇÐÀû±â¼ú
  • immunologic test
    ¸é¿ª°Ë»ç
  • immunologic thrombocytopenic purpura
    ¸é¿ª¼º Ç÷¼ÒÆÇ°¨¼Ò¼º ÀÚ¹Ý
  • immunologic tolerance
    ¸é¿ª°ü¿ë(Øóæ¹Î°é»)
  • immunologic tolerance
    ¸é¿ª°ü¿ë(¡­Î°é»)
  • platelet immunologic refractory state
    Ç÷¼ÒÆÇ¸é¿ªÇÐÀû ºÒÀÀ»óÅÂ(ÝÕëëßÒ÷¾)
  • Acquiered immune deficiency syndrome
    ÈÄõ¼º ¸é¿ª °áÇÌÁõÈıº
  • Fluorine deficiency
    ºÒ¼Ò°áÇÌÁõ(Ý×áÈÌÀù¹ñø)
  • Folate deficiency
    ¿±»ê°áÇÌÁõ(ç¨ß«ÌÀù¹ñø)
  • Iodine deficiency
    ¿äµå °áÇÌÁõ(ÌÀù¹ñø)
  • Iron deficiency anemia
    ö°áÇ̼ººóÇ÷(ôÑÌÀù¹àõÞ¸úì)
  • Rh deficiency syndrome
    Rh °áÇÌÁõÈıº
  • T cell deficiency
    T¼¼Æ÷°áÇÌ
  • abdominal muscle deficiency syndrome
    º¹±Ù°á¼ÕÁõÈıº(ÜÙÐÉÌÀáßñøý¦ÏØ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • immunologic reaction
    ¸é¿ª¹ÝÀÀ
  • immunologic rejection
    ¸é¿ªÇÐÀû °ÅºÎ.
  • immunologic response
    ¸é¿ª¹ÝÀÀ.
  • immunologic surveillance
    ¸é¿ª°¨½Ã(±â±¸).
  • immunologic system
    ¸é¿ª°è.
  • immunologic technique
    ¸é¿ªÇÐÀû±â¼ú
  • immunologic test
    ¸é¿ª°Ë»ç
  • immunologic thrombocytopenic purpura
    ¸é¿ª¼º Ç÷¼ÒÆÇ°¨¼Ò¼º ÀÚ¹Ý
  • immunologic tolerance
    ¸é¿ª°ü¿ë(Øóæ¹Î°é»)
  • immunologic tolerance
    ¸é¿ª°ü¿ë(¡­Î°é»)
  • platelet immunologic refractory state
    Ç÷¼ÒÆÇ¸é¿ªÇÐÀû ºÒÀÀ»óÅÂ(ÝÕëëßÒ÷¾)
  • abdominal muscle deficiency syndrome
    º¹±Ù°á¼ÕÁõÈıº(ÜÙÐÉÌÀáßñøý¦ÏØ).
  • acid lipase deficiency
    »ê¼º ¸®ÆÄÁ¦ °áÇÌÁõ(ß«àõ¡­ÌÀù¹ñø)
  • acquired immune deficiency
    ÈÄõ¼º ¸é¿ª°áÇÌ
  • acquired immune deficiency syndrome
    ÈÄõ¼º ¸é¿ª°áÇÌ ÁõÈıº
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Cytogenetic deficiency
    ¼¼Æ÷¹ß»ý°áÇÌ
    [¿¾ ¿ë¾î] ¼¼Æ÷¹ß»ý°áÇÌ
  • Stimulus deficiency
    ÀڱذáÇÌ
    [¿¾ ¿ë¾î] ÀڱذáÇÌ
  • Histogenetic deficiency
    Á¶Á÷¹ß»ý°áÇÌ
    [¿¾ ¿ë¾î] Á¶Á÷¹ß»ý°áÇÌ
  • Synthesis deficiency
    ÇÕ¼º°áÇÌ
    [¿¾ ¿ë¾î] ÇÕ¼º°áÇÌ
  • Hormone deficiency
    È£¸£¸ó°áÇÌ
    [¿¾ ¿ë¾î] È£¸£¸ó°áÇÌ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
IGD idiopathic growth hormone deficiency; interglobal distance; isolated gonadotropin deficiency
MCD magnetic circular dichroism; mast-cell degranulation; mean cell diameter; mean of consecutive differ...
AAMD American Association on Mental Deficiency; ¹Ì±¹ Á¤½Å ¹Ú¾à Çùȸ
AAMD-ABS American Association on Mental Deficiency-Adaptive Behavior Scale; ¹Ì±¹ Á¤½Å ¹Ú¾à Çùȸ ÀûÀÀ Çൿ ôµµ...
AIDS Acquired Immuno(Immune)-Deficiency Syndrome; ÈÄõ¼º ¸é¿ª °áÇÌ ÁõÈıº
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AMD Acid maltase deficiency
AIDS Acquire Immune Deficiency Syndrome
AIDS Acquired Immune Deficiency Disease Syndrome
alpha1ATD Alpha-1-antitrypsin deficiency
AATD Alpha1-antitrypsin deficiency
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cellular deficiency
    ¼¼Æ÷ °áÇÌ
    ¼¼Æ÷°¡ À¯ÀüÀû ȤÀº ÀÚ°¡¸é¿ªÀû ¿äÀÎÀ¸·Î ÀÎÇØ¼­ °áÇÌµÈ °Í.
  • chromosomal deficiency
    ¿°»öü °áÇÌ
  • color deficiency
    »ö °áÇÌ
  • deficiency anemia
    °áÇ̼º ºóÇ÷
    Ç÷»ö¼Ò °áÇÌÀ¸·Î ÀÎÇÑ ºóÇ÷.
  • deficiency symptom
    °áÇÌ Áõ»ó
    ³»ºÐºñ¼±ÀÇ ºÐºñ Àå¾Ö¿¡ ÀÇÇÑ Áõ»ó.
  • diphosphatase deficiency
    µðÆ÷½ºÆÄŸÁ¦ °áÇÌ
  • electrolyte deficiency syndrome
    ÀüÇØÁú °áÇÌ ÁõÈıº
  • erythropoietin deficiency anemia
    ¿¡¸®Æ®·ÎÆ÷¿¡Æ¾ °áÇ̼º ºóÇ÷, ÀûÇ÷±¸ Á¶Ç÷ ÀÎÀÚ °áÇ̼º ºóÇ÷
  • factor deficiency
    ÀÎÀÚ °áÇÌ, Á¦ÀÎÀÚ °áÇÌÁõ
  • factor IX deficiency
    Á¦ 9ÀÎÀÚ °áÇÌÁõ, Á¦9ÀÎÀÚ °áÇÌ
  • factor VII deficiency
    Á¦ 7ÀÎÀÚ °áÇÌÁõ
  • factor VIII deficiency
    Á¦ 8ÀÎÀÚ °áÇÌ
  • factor XI deficiency
    Á¦11ÀÎÀÚ °áÇÌ
    ÀÌ ÀÎÀÚ°¡ ºÎÁ·µÇ¸é Ç÷¿ìº´ C³ª Rosenthal ÁõÈıºÀ¸·Î ºÒ¸®´Â Àü½Å¼º Ç÷¾× ÀÀ°í Àå¾Ö¸¦ ÀÏÀ¸Å°´Âµ¥ °íÀüÀû Ç÷¿ìº´°ú À¯»çÇÏ´Ù.
  • folate deficiency anemia
    ¿±»ê °áÇ̼º ºóÇ÷
  • folic acid deficiency anemia
    ¿±»ê °áÆð¼º ºóÇ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
myofascial pain syndromes Muscular pain in numerous body regions that can be reproduced by pressure on trigger points, localised hardenings in skeletal muscle tissue. Pain is referred to a location distant from the trigger points. A prime example is the temporomandibular joint dysfunction syndrome.
(12 Dec 1998)
postgastrectomy syndromes Sequelae of gastrectomy from the second week after operation on. Include recurrent or anastomotic ulcer, postprandial syndromes (dumping syndrome and late postprandial hypoglycaemia), disordered bowel action, and nutritional deficiencies.
(12 Dec 1998)
pre-excitation syndromes Conditions characterised by activation of the whole or some part of the ventricle by the atrial impulse earlier than would be expected if the impulse reached the ventricle by way of the normal specific conduction system only.
(12 Dec 1998)
cytotoxicity, immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitised T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
(12 Dec 1998)
cytotoxicity tests, immunologic The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitised lymphocyte, an antibody, or complement.
(12 Dec 1998)
sleep apnea syndromes Disorders involving apneic episodes during sleep. They may be due to cessation of diaphragmatic movement, obstruction of upper airway air flow, or a combination of these, and may be associated with hypersomnolence, insomnia, or obesity.
(12 Dec 1998)
neoplastic endocrine-like syndromes Endocrine syndromes due to hormone production by neoplasms of non-endocrine tissue, or by other than the usual endocrine tissues. They are often the first indication of a previously undetected neoplasm.
(12 Dec 1998)
neoplastic syndromes, hereditary The condition of a pattern of malignancies within a family, but not every individual's necessarily having the same neoplasm. Characteristically the tumour tends to occur at an earlier than average age, individuals may have more than one primary tumour, the tumours may be multicentric, usually more than 25 percent of the individuals in direct lineal descent from the proband are affected, and the cancer predisposition in these families behaves as an autosomal dominant trait with about 60 percent penetrance.
(12 Dec 1998)
nerve compression syndromes Repeated or prolonged pressure on a nerve root or peripheral nerve leading to ischemia, the response to which is oedema above and below the source of pressure. If the pressure is not relieved, fibrosis tends to develop. Types of nerve compression syndromes are the neuropathy caused by intervertebral disk herniation, compression of the median nerve in the carpal tunnel, compression of the ulnar nerve in the elbow, and compression of the lateral cutaneous nerve of the thigh in meralgia paresthetica. This is also called pressure neuropathy.
(12 Dec 1998)
suppressor factors, immunologic Proteins, protein complexes, or glycoproteins secreted by suppressor T-cells that inhibit either subsequent T-cells, B-cells, or other immunologic phenomena. Some of these factors have both histocompatibility (I-j) and antigen-specific domains which may be linked by disulfide bridges. They can be elicited by haptens or other antigens and may be mass-produced by hybridomas or monoclones in the laboratory.
(12 Dec 1998)
syndromes of paranasal sinuses <radiology> Gardner: osteomas, Kartagener: chronic infection, basal cell-nevoid, neurofibromatosis, Down (trisomy 21): hypoplastic frontal, sphenoid, with or without ethmoid, progeria: absent frontal sinuses; dwarf, immature, cleidocranial dysostosis: all sinuses absent/small
(12 Dec 1998)
desensitization, immunologic Immunosuppression by the administration of increasing doses of antigen. Though the exact mechanism is not clear, the therapy results in an increase in serum levels of allergen-specific IgG, suppression of specific IgE, and an increase in suppressor T-cell activity.
(12 Dec 1998)
dose-response relationship, immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
(12 Dec 1998)
dry eye syndromes Corneal and conjunctival dryness due to deficient tear production, predominantly in menopausal and post-menopausal women. Filamentary keratitis or erosion of the conjunctival and corneal epithelium may be caused by these disorders. Sensation of the presence of a foreign body in the eye and burning of the eyes may occur.
(12 Dec 1998)
immunologic <immunology> Pertaining to immunology.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á